BioMed Research International / 2015 / Article / Tab 2

Research Article

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment

Table 2

Characteristics of the treated and untreated (contemporary and historical) cohorts [aim 2]. All comprise relapsing-onset MS patients aged ≥50 at interferon beta eligibility date (baseline).

Characteristics (at , unless otherwise stated)Interferon beta-treated patients ()Contemporary untreated ()Historical untreated    ()

Sex, (%)
 Male17 (18.9)51 (29.8)24 (22.6)
 Female73 (81.1)120 (70.2)82 (77.4)
Age at MS onset, years (mean ± SD)43.3 ± 11.640.7 ± 11.10.08**41.0 ± 11.7
(%)
3013 (14.4)36 (21.1)20 (18.9)
 30–<4019 (21.1)38 (22.2)22 (20.8)
 40–<5027 (30.0)55 (32.2)39 (36.8)
5031 (34.4)42 (24.6)25 (23.6)
Disease duration, years (mean ± SD; median [range])10.9 ± 10.7;
7.5 [0.03–43.5]
14.9 ± 11.4;
13.3 [0.2–53.3]
15.1 ± 12.1;
12.4 [0.3–47.9]
Age, years (mean ± SD) 54.2 ± 4.555.6 ± 4.956.1 ± 5.5
(%)
 50–<5565 (72.2)95 (55.6)55 (51.9)
 55–<6016 (17.8)54 (31.6)28 (26.4)
609 (10.0)22 (12.9)23 (21.7)
EDSS score (mean ± SD; median [range])2.5 ± 1.2;
2.5 0–6
2.5 ± 1.2;
2.5 [0–6.5]
2.4 ± 1.2;
2.5 [0–6]
Annualized relapse rate in the two years prior to (mean ± SD)0.6 ± 0.70.4 ± 0.60.4 ± 0.6
Active follow-up time (first to last EDSS assessment), years (mean ± SD)5.1 ± 2.74.3 ± 2.78.6 ± 5.1<0.00
Charlson comorbidity (median [range])
(%)0 0-10 [0–3]
 0 (no comorbidity)85 (94.4)164 (95.9)
1 (at least one comorbid condition)5 (5.6)7 (4.1)
Neighbourhood income , (%)
 1 (lowest income)12 (13.6)33 (20.2)
 211 (12.5)33 (20.2)
 316 (18.2)28 (17.2)
 419 (21.6)30 (18.4)
 5 (highest income)30 (34.1)39 (23.9)

EDSS, Expanded Disability Status Scale.
Baseline was considered as the first date a patient became eligible for interferon beta treatment (whilst being >=50 years old).
Untreated patients who first became eligible for treatment in the “interferon beta era” (whilst being >=50 years old).
Comparison of the interferon beta-treated patients with the contemporary untreated patients.
Untreated patients who first became eligible for treatment in the “pre-interferon beta era” (whilst being >=50 years old).
Comparison of the interferon beta-treated patients with the historical untreated patients.
Pearson’s chi-square test.
Student’s -test.
Mann-Whitney-Wilcoxon test.
If this period included MS onset, the first onset attack was not included as a relapse.
Deyo adaptation of the Charlson comorbidity index, based on hospital admissions or physician visits in the two years prior to baseline and derived from International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, excluding hemiplegia, paraplegia, and dementia to avoid misclassifying complications of MS as comorbidity. All relevant comorbidities were aggregated into a single variable theoretically ranging from 0 to 33; higher scores indicate more comorbidity.
Data incomplete/unavailable.
Used as a proxy for socioeconomic status. Data were missing for 2 patients in the interferon beta-treated cohort and 8 patients in the contemporary control cohort.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.